GleamWall
中文EN

GLSI Greenwich LifeSciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1799788 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-27.9%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-107,371.7%
ROA-481.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets129.6%
Debt / equity—
Current ratio0.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.55x
Accruals ratio-217.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.45M$3.56M$5.21M$7.59M$3.27M$3.42M$2.27M$6.16M
SG&A expense$412,695$462,931$518,190$355,194$466,926$352,838$497,602$1.93M
Operating income-$5.86M-$4.02M-$5.73M-$7.94M-$3.73M-$3.77M-$2.77M-$8.08M
Net income-$5.81M-$3.95M-$5.66M-$7.92M-$3.71M-$3.75M-$2.74M-$8.04M
EPS (basic)-0.40-0.27-0.39—-0.27-0.28-0.21—
EPS (diluted)-0.40-0.27-0.39—-0.27-0.28-0.21—
Weighted avg. shares (diluted)14.68M14.62M14.57M—13.64M13.37M13.17M—
Balance sheet
Cash & equivalents$5.90M$8.88M$10.51M$6.18M$3.81M$3.13M$2.75M$4.09M
Current assets$5.90M$8.88M$10.51M$6.18M———$4.09M
Intangibles——————$876$1,779
Total assets$5.90M$8.88M$10.51M$6.18M$3.81M$3.13M$2.75M$4.09M
Current liabilities$7.65M$5.76M$5.24M$5.82M$1.62M$1.69M$1.44M$3.19M
Total liabilities$7.65M$5.76M$5.24M$5.82M$2.02M$2.52M$2.55M$3.19M
Shareholders' equity-$1.75M$3.12M$5.27M$353,217$1.79M$604,302$200,483$908,626
Shares outstanding14.68M14.68M14.67M14.30M13.79M13.47M13.19M13.15M
Cash flow statement
Operating cash flow-$2.98M-$1.94M-$4.70M-$3.17M-$2.67M-$2.23M-$1.83M-$1.85M
Financing cash flow$0$310,664$9.03M$5.55M$3.35M$2.61M$492,423$121,829
Stock-based compensation$949,692$1.48M$1.54M$2.17M$1.54M$1.54M$1.54M$5.47M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.